Study
Mesenchymal stromal cell-based therapy in the COVID-19 pandemic: results from an academic phase I/II double-blind, randomized, placebo-controlled clinical trial and reflections for the field.
In 26 hospitalized patients with COVID-19 ARDS, Wharton’s Jelly MSCs were well tolerated but did not improve mortality, ventilation duration, or ICU stay.
Summary Can stem cells improve survival or recovery from severe COVID-19 lung failure? Show / hide ↓
Researchers randomly assigned 26 hospitalized people with COVID-19 and acute respiratory distress syndrome, a dangerous form of lung failure, to receive either umbilical-cord tissue cells or a placebo, a dummy treatment. Twenty-five people received two treatments: 13 got the cells and 12 got the placebo. The cell treatment caused no serious treatment-related problems, but it did not clearly reduce deaths, time on a breathing machine, or time in intensive care. Two people in the placebo group died, compared with none in the cell group, but the study was too small to show that this difference was meaningful.
What this means for you: This small study does not show that these cells help people recover from severe COVID-19. It is not a reason to buy stem-cell treatments or use them outside properly supervised research.
early evidenceTorres and colleagues report the COVIDMES multicenter Phase I/II pilot trial of Wharton’s Jelly-derived mesenchymal stromal cells in hospitalized patients with moderate-to-severe COVID-19 ARDS. Twenty-six patients were enrolled and 25 received two intravenous doses: 13 received 1×10^6 viable cells per kilogram and 12 received placebo. No treatment-related serious adverse events occurred. There was no statistically significant difference in 28-day mortality: zero deaths with MSC treatment versus two with placebo, P=0.18. Mechanical ventilation lasted 18.3 days with MSCs and 10.6 days with placebo, P=0.08. ICU stay was 17.1 versus 11.9 days, P=0.11. Ferritin declined more over time in the MSC group, but the biomarker change was not linked to clinical improvement. This is a useful negative study for the MSC evidence base. It supports short-term feasibility and safety in this small setting, but it does not support efficacy for ARDS. It also shows why biomarker movement cannot substitute for survival, ventilation, or functional outcomes. The cells, dose, timing, and disease context are specific. The result should not be generalized to frailty, osteoarthritis, Alzheimer’s disease, or commercial anti-aging infusions.
In this exploratory pilot study, WJ-MSCs demonstrated a favorable safety profile and evidence of biochemical immunomodulation but no clinical efficacy in moderate-to-severe COVID-19 associated ARDS. These findings highlight the challenges of evaluating advanced therapy medicinal products within a rapidly evolving standard of care and support the need for biomarker-guided patient stratification and optimized dosing strategies in future MSC trials. The successful execution of this trial also validates the resilience of academic "donor-to-patient" networks in global health emergencies.
The trial enrolled only 26 people and was conducted during earlier COVID-19 waves. Mortality and clinical secondary outcomes were not statistically different. The result is disease- and product-specific. It does not test longevity or anti-aging outcomes.
Cited by
1 encyclopedia entries reference this study.